Game-changing cancer therapeutics are urgently needed
Our lead program is focused on Acute Myeloid Leukaemia (AML). AML is the most aggressive form of blood cancer and is notoriously difficult to detect and treat. Most patients are diagnosed late when their cancer has already progressed and often present with challenging co-morbidities, making successful treatment problematic.
- Survival rates for this cancer remain dismally low; one of the lowest across all cancers
- Most next generation therapeutic approaches are failing to deliver in this area due to extreme toxicity
- This has resulted in no significant breakthroughs in patient outcomes for decades